Guidelines for prevention, surveillance, diagnosis, and treatment, in this new era of more virulent strains of antibiotic associated diarrhea (AAD), Clostridium difficile-associated diseases/diarrhea (CDAD) and Clostridium difficile colitis (CDAC)

Practical Gastroenterology

Volumn 30, Issue 6, 2006, Pages 65-82

  Hookman, Perry ^a   Barkin, Jamie S ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; ANTIBIOTIC AGENT; BACITRACIN; BACTERIAL TOXIN; CIPROFLOXACIN; COLESTYRAMINE; FUSIDIC ACID; GATIFLOXACIN; HISTAMINE H2 RECEPTOR ANTAGONIST; METRONIDAZOLE; MOXIFLOXACIN; PROBIOTIC AGENT; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC ASSOCIATED DIARRHEA; ANTIBIOTIC RESISTANCE; BACTERIAL MUTATION; BACTERIAL STRAIN; BACTERIAL VIRULENCE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE ASSOCIATED COLITIS; CLOSTRIDIUM DIFFICILE ASSOCIATED DIARRHEA; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; EARLY DIAGNOSIS; EPIDEMIC; GENETIC VARIABILITY; HEALTH CARE FACILITY; HIGH RISK POPULATION; HOSPITAL INFECTION; HOSPITAL PATIENT; HUMAN; NONHUMAN; PRESCRIPTION; PSEUDOMEMBRANOUS COLITIS; REVIEW; RISK FACTOR; TOXIC MEGACOLON;

EID: 33745685265     PISSN: 02774208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Kallen J, et al. Current Antibiotic Therapy for Isolated Urinary Tract Infections in Women. Arch Internal Medicine, 2006;166: 635-639.
2. Jernigan, D. CDC Division of Epidemiology; presentation at the December, 2005 InterScience Conference on Anti-microbial Agents & Chemotherapy; Washington D.C.
3. Ackermann G, Thomalla S, Ackermann F, Schaumann R, Rodloff AC, Ruf BR. Prevalence and characteristics of bacteria and host factors in an outbreak situation of antibiotic-associated diarrhoea. J Med Microbiol, 2005;54(Pt 2):149-153.
4. Clancy MJ, et al. The widespread emergence of Methicillin resistance in community acquired S. aureus infections in Denver. South Med J, 2005; 98:1069.
5. DeFrancesco V, et al. Clarithromycin-Resistant Genotypes and Eradication of Helicobacter pylori. Ann Int Med, 2006; 144(2):94.
6. McDonald LC, Killgore GE, et al. An Epidemic, Toxin Gene-Variant Strain of Clostridium difficile NEJM. 2005; 353:2433-2441.
7. Loo VG, Poirier L, Mark A, Miller MA. A Predominantly Clonal Multi-Institutional Outbreak of Clostridium Difficile-Associated Diarrhea with High Morbidity and Mortality. NEJM, 2005; 353:2442-2449.
8. Severe Clostridium difficile-associated disease in populations previously at low risk-in four states. MMWR, 2005;54:1201-1205.
9. Johal SS, Hammond J, Solomon K, James PD, Mahida YR. Clostridium difficile-associated diarrhoea in hospitalised patients: onset in the community and hospital and role of flexible sigmoidoscopy. Gut, 2004;53:673-677.
10. Starr J. Clostridium difficile-associated diarrhoea: diagnosis and treatment. BMJ, 2005; 331:498-501.
11. Bartlett JG. Antibiotic-associated diarrhea. NEJM, 2002;346: 334-339.
12. Johnson S, Samore MH, Farrow KA, et al. Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals. NEJM, 1999;34l: 1645-1651.
13. Pepin J, Valiquette L, Alary ME, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ, 2004; 171:466-472.
14. Muto CA, Pokrywka M, Shutt K, et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased, fluoroquinolone use. Infect Control Hosp Epidemiol, 2005;26:273-280.
15. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. NEJM, 2005;353: 2442-2449.
16. Biller P, Shank B, Tkatch L, Lind L, McDonald LC. Moxifloxacin use as a risk factor in an outbreak of Clostridium difficile-associated disease. In: Proceedings of the 2005 Annual Conference of the Association for Professionals in Infection Control and Epidemiology, Baltimore, June 19-21, 2005.
17. Gaynes R, Rimland D, Killum E, et al. Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use. Clin Infect Dis, 2004;38:640-645.
18. Comments in: Ref Source. Clin Inf Dis, 2004, 39 (4):602;
19. Clin Inf Dis, 38(5):646;
20. Clin Inf Dis, 39(6):875.
21. Brown-Elliot BA, et al. Comparison of in vitro activities of Gatigloxacin and ciprofloxacin against four types of rapidly growing mycobacteria. Antimicr Agents Chemother, 2002; 46(10):3283.
22. Pendland SL, et al. Comparative killing rates of gatifloxacin and ciprofloxacin against 14 clinical isolates; impact of bacterial strain and antibiotic concentration. Diagn Microb Infect Dis, 2002;44(1):59.
23. Huczko E, et al. Susceptibility of bacterial isolates to gatifloxacin and ciprofloxacin from clinical trials 1997-1998. Int J Antimicr Agents, 2000;16(4):401.
24. Jorgensen JH, et al. Activities of clinafloxacin, gatifloxacin and trovafloxacin against recent clinical isolates of levofloxacin resistant Strep Pneumon. Antimicr Agents Chemother, 2000; 44(11):2962.
25. Clabots CR, et al. Acquisition of C. difficile by hospitalized patients for colonized new admissions as a source of infection. J Infect Dis, 1992 166:561.
26. McFarland LV, et al. Risk Factors for C. difficile carriage and CDAD in a cohort of hospitalized patients. J Infect Dis, 1990 162:678.
27. Dial S, et al. Use of Gastric Acid-Suppressive Agents and the Risk of Community-Acquired Clostridium Difficile-Associated Disease. JAMA, 2005;294:2989-2995.
28. Bliss DZ, Johnson S, Savik K, Clabots CR, Willard K, Gerding DN. Acquisition of Clostridium difficile and Clostridium difficile-associated diarrhea in hospitalized patients receiving tube feeding. Ann Intern Med, 1998;129(12):1012-1019.
29. Ackermann G, Thomalla S, Ackermann F, Schaumann R, Rodloff AC, Ruf BR. Prevalence and characteristics of bacteria and host factors in an outbreak situation of antibiotic-associated diarrhoea. J Med Microbiol, 2005;54(Pt 2):149-153.
30. Rubin MS, Bodenstein LE, Kent KC. C. Difficile-Associated Colitis. Dis Colon Rectum, 1995;38(4):350-354.
31. Gan SI. "A New Look at Toxic Megacolon: An Update & Review of Incidence, Etiology, Pathogenesis, and Management. Amer J Gastro, 2003;98(11):2363.
32. Wullt M, et al. Activity of 3 different disinfectants and acidified nitrite against C. difficile spores. Infect Control Hosp Epidemio, 2003;24:765-768.
33. Johnson S, et al. Prospective controlled study of vinyl glove use to interrupt C. difficile nosocomial transmission. Am J Med, 1990;88:137-140.
34. Johnson S, Homann SR, Bettin KM, Quick JN, Clabots CR, Peterson LR, Gerding DN. Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo-controlled trial. Ann Intern Med, 1992;117(4):297-302.
35. Schroeder MS. C. difficile Diarrhea. Am Fam Physician, 2005; 71:921.
36. Oldfield CD. CDAD. Rev Gastr Dsrdrs, 2004; 4:186.
37. Pepin J, Valiquette L, Alary ME, Villemure P, Pelletier A, Forget K, Pepin K, Chouinard D. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ, 2004;171(5):466-472.
38. Wilcox MH, Howe R. Diarrhoea caused by Clostridium difficile: response time for treatment with metronidazole and vancomycin. Am J Gastroenterol, 2002;97(7):1769-1775.
39. Bricker E, Garg R, Nelson R, Loza A, Novak T, Hansen J. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst Rev, 2005;(1):CD004610.
40. Nomura K, et al. Successful treatment with rifampin for fulminant antibiotic associated colitis in a patient with non Hodgkin's lymphoma. WJ Gastroenterol, 2004;10(5):765.
41. Kurtz CB, Cannon E, et al. GT160-246, a Toxin Binding Polymer for Treatment of Clostridium difficile Colitis. Antimicrobial Agents and Chemotherapy, 2001;Vol 45(8): 2340-2347.
42. Spellberg B, et al. Trends in antimicrobial drug development: implications for the future. Clin Infect Dis, 2004; 38:1279.
43. Bricker E, Garg R, Nelson R, Loza A, Novak T, Hansen J. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst Rev, 2005; (1):CD004610.
44. Jacobs A, et al. Extra colonic manifestations of C. difficile infections. Medicine, 2001; 80:88.
45. Johnson S, et al. Treatment of C. difficile. Ann Intern Med, 1992; 117:297.
46. Yassin SF, et al. C. difficile-associated diarrhea and colitis. Mayo Cl Proc, 2001; 76:725.
47. Cleary RK. C. difficile-Associated Diarhea and Colitis. Dis Colon & Rectum, 1998; 41(11):1435.
48. Hurley B, et al. The spectrum of pseudomembranous colitis and Antibiotic associated diarrhea. Arch Int Med, 2002;162:2177.
49. Dendukuri N, Costa V, McGregor M, Brophy JM. Probiotic therapy for the prevention and treatment of Clostridium difficile-associated diarrhea: a systematic review. CMAJ, 2005;173(2): 167-170.
50. McFarland LV, Meta-Analysis of Probiotics for the Prevention of Antibiotic Associated Diarrhea(AAD) and the Treatment of Clostridium Difficile Disease(CDD). Am J Gastroent, 2006;101: 812-822.
51. Vasa CV, Glatt AE. Effectiveness and appropriateness of empiric metronidazole for Clostridium difficile-associated diarrhea. Am J Gastroenterol, 2003;98(2):354-358.
52. Kallenbach G. Antibiotic associated diarrhea in the elderly. Rev Med Intern, 2004; 25:46.
53. Manabe YC. C. difficile Colitis: an efficient clinical approach to diagnosis. Ann Int Med, 1995; 123:835.
54. Bentley WD, et al. Practice Guidelines for Evaluation of Fever & Infection in LTCFs. CID, 2000; 31:640.
55. Boyce JM, Pittet D. Guideline for hand hygiene in health-care settings: recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Infect Control Hosp Epidemiol, 2002;23:Suppl:S3-S40.
56. Garner JS. Guideline for isolation precautions in hospitals. Infect Control Hosp Epidemiol, 1996; 17:53-80.
57. Sehulster L, Chinn RY. Guidelines for environmental infection control in health-care facilities: recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep, 2003;55:1-42.
58. Barbut F, et al. Epidemiology of C. difficile-associated infections. Clin Microb Infect, 2001; 7(8):405.
59. Gerding DN, Johnson S, Peterson LR, Mulligan ME, Silva J Jr. Clostridium difficile-associated diarrhea and colitis. Infect Control Hosp Epidemiol, 1995;16:459-477.
60. Davey P, Brown E, Fenelon L, Finch R, Gould I, Hartman G, Holmes A, Ramsay C, Taylor E, Wilcox M, Wiffen P. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database of Systematic Reviews, 2005, Issue 4. Art. No.: CD003543. DOI: 10.1002/14651858.CD003543.pub2.
61. Park-Wyllie LY, et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. NEJM, 2006;354(13):1352-1361.
62. Simor AE, et al. SHEA Position Paper: C. Difficle in LTCFs for the Elderly. Infect Control Hosp Epid, 2002; 23(11):696-703.
63. Furuno JP. Identiying Groups at High Risk for Carriage of Antibiotic-Resistant Bacteria. Archives Internal Medicine, 2006; 166:580-585.
64. Thibault A, Miller MA, Gaese C. Risk factors for the development of Clostridium difficile-associated diarrhea during a hospital outbreak. Infect Control Hosp Epidemiol, 1991;12(6):345-348.
65. Bartlett JG, Perl, TM. The New Clostridium Difficile-What Does It Mean? NEJM, 2005; 353:2503.